» Articles » PMID: 9509898

Neural Actions of Immunophilin Ligands

Overview
Specialty Pharmacology
Date 1998 Mar 24
PMID 9509898
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Immunophilins, protein receptors for immunosuppressant drugs such as cyclosporin A and FK506, are enriched far more in the brain than in the immune system. Drug-immunophilin complexes bind to calcineurin, inhibiting its phosphatase activity and leading to immunosuppressant effects. The immunophilin FKBP-12 (FK506 binding protein, 12 kDa) forms a complex with the ryanodine and inositol (1,4,5) trisphosphate (IP3) receptors to regulate their physiological release of intracellular Ca2+. Here, Solomon Snyder and colleagues describe how non-immunosuppressant as well as immunosuppressant immunophilin ligands are neurotrophic for numerous classes of damaged neurones, both in culture systems and intact animals. Their ability to stimulate functional regrowth of damaged sciatic, cortical cholinergic, dopamine and 5-HT neurones may have therapeutic relevance.

Citing Articles

Penile Rehabilitation and Treatment Options for Erectile Dysfunction Following Radical Prostatectomy and Radiotherapy: A Systematic Review.

Nicolai M, Urkmez A, Sarikaya S, Fode M, Falcone M, Albersen M Front Surg. 2021; 8:636974.

PMID: 33738297 PMC: 7961076. DOI: 10.3389/fsurg.2021.636974.


Copenhagen Head Injury Ciclosporin Study: A Phase IIa Safety, Pharmacokinetics, and Biomarker Study of Ciclosporin in Severe Traumatic Brain Injury Patients.

Kelsen J, Karlsson M, Hansson M, Yang Z, Fischer W, Hugerth M J Neurotrauma. 2019; 36(23):3253-3263.

PMID: 31210099 PMC: 6857463. DOI: 10.1089/neu.2018.6369.


Cyclosporin A attenuating morphine tolerance through inhibiting NO/ERK signaling pathway in human glioblastoma cell line: the involvement of calcineurin.

Rashki A, Mumtaz F, Jazayeri F, Shadboorestan A, Esmaeili J, Ejtemaei Mehr S EXCLI J. 2019; 17:1137-1151.

PMID: 30713473 PMC: 6341459. DOI: 10.17179/excli2018-1693.


CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations.

Yadav S, Pawar G, Kulkarni P, Ferris C, Amiji M J Pharmacol Exp Ther. 2018; 370(3):843-854.

PMID: 30591529 PMC: 6806630. DOI: 10.1124/jpet.118.254672.


FKBP Ligands-Where We Are and Where to Go?.

Kolos J, Voll A, Bauder M, Hausch F Front Pharmacol. 2018; 9:1425.

PMID: 30568592 PMC: 6290070. DOI: 10.3389/fphar.2018.01425.